Low-cost Mobile Oral Cancer Screening for Low Resource Setting

资源匮乏的低成本移动口腔癌筛查

• 批准号: 9031360
• 负责人: Rongguang Liang
• 金额: $ 49.88万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9031360
• 关键词: Accounting; Acute; Address; Adherence; Algorithms; Asians; Cancer Center; Cancerous; Car Phone; Cellular Phone; Chronic; Clinical; Collaborations; Computer software; Dental; Detection; Device Designs; Devices; Diagnosis; Diagnostic; Disease Progression; Early Diagnosis; Engineering; Evidence based intervention; FDA approved; Far East; Feedback; Goals; Health; Health Care Costs; Health Expenditures; Health Personnel; Healthcare; Human papilloma virus infection; Image; Image Analysis; Imaging Device; Incidence; India; Individual; Instruction; International; Lead; Lesion; Life; Light; Malignant - descriptor; Malignant Neoplasms; Modality; Morbidity - disease rate; Oral; Oral health; Oropharyngeal Squamous Cell Carcinoma; Participant; Patients; Performance; Phase; Population; Populations at Risk; Prevention; Prevention strategy; Quality of life; Recruitment Activity; Research Infrastructure; Resolution; Resources; Roswell Park Cancer Institute; Rural; Science; Screening for Oral Cancer; Site; Specialist; Stage at Diagnosis; Staging; Survival Rate; System; Treatment outcome; Triage; Work; base; cancer prevention; community setting; cost; diagnostic accuracy; follow-up; health literacy; high risk; image processing; imaging modality; imaging platform; imaging probe; imaging system; improved; low and middle-income countries; malignant mouth neoplasm; medical specialties; mobile application; mortality; multidisciplinary; novel; oncology; oral lesion; prototype; public health relevance; rural area; screening; tool; treatment strategy; trend; validation studies; young adult

 DESCRIPTION (provided by applicant): Oral and oropharyngeal squamous cell carcinoma (OSCC) together rank as the sixth most common cancer worldwide, accounting for approximately 400,000 new cancer cases each year. About two-thirds of these cancers occur in low- and middle-income countries (LMICs), with very high rates in South and South-East Asian. While the 5-year survival rate in the U.S. for OSCC is 62%, the survival rate is only 10-40% and the cure rate around 30% in the developing world. Low survival rate is primarily attributed to the delay in diagnosis and the resultant progression of disease to an advanced stage at diagnosis. This problem is more acute in LMICs where least amount of resources is available for health care expenditure. Diagnosis is often delayed in marginalized at-risk populations living in rural areas with poor access to specialty health care, low health literacy, and problematic adherence to follow up. Early diagnosis offers the best chance to improved treatment outcomes and survival for an individual diagnosed with OSCC. Diagnosis of early oral lesions requires effective screening of the population. It is also important to detect and diagnose the chronic and malignant oral lesions, so efficient prevention and treatment strategies can be devised. We propose a mobile intra-oral imaging device and image platform to address the urgent need of a low-cost, portable, easy to use, and reliable imaging device for oral cancer screening in low resource settings. To achieve this goal, we have formed an international, multidisciplinary team with complementary expertise in engineering, oncology, and manufacturing/distribution. We have one of the largest cancer centers (Mazumdar- Shaw Cancer Center (MSCC), India) in LMIC to demonstrate the functionalities and validate clinical performance of the proposed device for oral cancer screening in low resource settings. We also have a collaboration with one of the largest dental companies (Carestream Health Inc) in the world to fabricate and distribute the products. We will develop prototypes in the UH2 Phase and demonstrate the functionalities and suitability in low resource setting at Roswell Park Cancer Institute and MSCC. In the UH3 Phase, we will refine the mobile intra-oral imaging device, and validate the clinical usefulness in four rural districts in Bangalore. This project is significant because early diagnosis of oral lesins and timely patient referral to specialists can reduce disease progression, reduce morbidity and mortality, and cut healthcare costs. We expect that use of this mobile based dual-modality screening approach for early diagnosis of oral cancers in community settings will eventually improve detection rates, treatment outcomes, and quality of life of patients.

 描述（由适用提供）：口服和口腔咽部鳞状细胞癌（OSCC）一起排名全球第六个最常见的癌症，每年约为400,000例新的癌症病例。这些癌症中约有三分之二发生在低收入和中等收入国家（LMIC），南亚和东南亚的率很高。美国OSCC的5年生存率为62％，但在发展中国家的生存率仅为10-40％，治愈率约为30％。低存活率主要归因于诊断的延迟以及疾病导致的诊断阶段。在LMIC中，此问题更为敏锐，在这里，最少的资源可用于医疗保健支出。在农村地区的边缘化高危人群中，诊断通常会被延迟，无法获得专业医疗保健，健康素养低以及有问题的跟进。早期诊断提供了改善治疗结果和使用OSCC个人诊断的生存的最佳机会。早期口腔病变的诊断需要有效筛查人群。检测和诊断慢性和恶性口腔病变也很重要，因此可以设计有效的预防和治疗策略。我们提出了一种移动的口腔内成像设备和图像平台，以应对低成本，便携，易于使用和可靠的成像设备的迫切需要，以便在低资源设置中进行口腔癌筛查。为了实现这一目标，我们组成了一个国际多学科团队，具有完整的工程，肿瘤学和制造/分销方面的专业知识。我们拥有LMIC最大的癌症中心（MAZUMDAR-SHAW癌症中心（MSCC））之一，以证明在低资源环境中提议的口腔癌筛查设备的临床性能并验证临床性能。我们还与世界上最大的牙科公司之一（Carestream Health Inc）进行了合作，以制造和分发产品。我们将在UH2阶段开发原型，并在Roswell Park Cancer Institute和MSCC的低资源环境中证明功能和适用性。在UH3阶段，我们将完善移动内部成像设备，并验证临床实用性 班加罗尔的四个粗糙地区。该项目很重要，因为早期诊断口腔限制和及时的患者转诊可以减少疾病进展，降低发病率和死亡率并降低医疗保健成本。我们预计，在社区环境中，使用这种基于移动的双模式筛查方法对口服癌症的早期诊断最终将提高患者的检测率，治疗结果和生活质量。